Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database

Abstract

Triple-positive breast cancer (TPBC), i.e. HER2-positive (HER2+) and hormone receptors-positive breast cancer, is a specific subgroup of breast cancers. TPBC biology is characterized by strong mutual interactions between signaling pathways stimulated by estrogens and HER2 amplification. The present study aims to carry out a population-based analysis of treatment outcomes in a cohort of hormone receptor (HR) positive and negative breast cancer patients who were treated with anti-HER2 therapy in the Czech Republic. The BREAST research database was used as the data source for this retrospective analysis. The database covers approximately 95% of breast cancer patients treated with targeted therapies in the Czech Republic. The analysis included 6,122 HER2-positive patients. The patients were divided into two groups, based on estrogen receptor (ER) or progesterone receptor (PR) positivity: hormone receptor negative (HR-) patients had both ER-and PR-negative tumors (n = 2,518), unlike positive (HR+) patients (n = 3,604). HR+ patients were more often diagnosed premenopausal at the time of diagnosis, presented more often at stage I or II and their tumors were less commonly poorly differentiated. The overall survival (OS) was significantly higher in subgroups of HR+ patients according to treatment setting. When evaluated by stages, significantly higher OS was observed in HR+ patients diagnosed at stages II, III, and IV and regardless of tumor grade.

The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database

“…However, the results pertaining to HER2+ status were not entirely consistent. Previous studies [18][19][20][21][22] have reported a similar association between ER+ and PR+ status and improved OS, DSS, and progression-free survival, for both male and lactating breast cancer. Tis aligns with our fndings, although we did not observe any correlation between ER−/PR+ status and clinical outcomes in BC-LuC due to the limited sample size.…”

Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients

“…The higher incidence of nodes involvement and local advanced stage could be partially related to the screening suspension and delayed diagnosis (6). Additionally, we observed a different distribution of cancer grades, which could also be partially correlated with lymph nodes advanced stages (26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39). Nonetheless, at multivariate analysis, waiting time on list, significantly longer during the Lockdown, seems to be the only predictive factor of lymph nodes involvement progression.…”

Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer

“…Out of 6,122 patients who met the above-mentioned criteria, a total of 4,532 patients were included in the analysis after balancing the data by propensity score matching (R statistical software with MatchIt package) with respect to age (p=0.335 after matching) and grade (p=0.998 after matching). The propensity score matching analysis followed the population analysis in a previous manuscript by the same authors focused on comparison of patients' groups according to their ER and/or PR receptor status in the real-world settings (10). Classified according to their ER and/or PR receptor status, the two resulting groups contained approximately the same numbers of patients, patients with both ER-and PR-negative (n=2,268) and patients with either ER or PR positive (n=2,264 Statistical analysis.…”